Related Experiment Video
Updated: May 7, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
The Diagnostic Role and Potential Pharmacological Value of DDR1 in Pan-Cancer
Yi Yu1, Yonggang Tian1, Dekui Zhang1
1Department of Gastroenterology, Lanzhou University Second Hospital, Cuiyingmen, No. 82, Chengguan District, Lanzhou 730030, Gansu Province, China.
Introduction:
Cancer remains a devastating global health burden. Despite the identification of numerous biological targets, effective therapeutic agents remain limited. As a highly promising novel target, the role of Discoid Domain Receptors (DDRs) in pan-cancer biology is still poorly characterized. Thus, this study aims to elucidate the regulatory mechanisms and diagnostic potential of DDR1 across different cancer types.
Methods:
Herein, we used UCSC, SangerBox, GEPIA, GSCA, and GeneMANIA online databases to analyze the expression and role of DDR1 in pan-cancer.
Results:
The expression levels of DDR1 showed significant differences in some tumour T, N, and M stages. Importantly, DDR1 expression was associated with clinical prognosis in five cancers. In addition, DDR1 was inversely correlated with most immune checkpoint pathways, immunomodulatory genes, and immune cell infiltration in a few cancers. Furthermore, in most cancers, DDR1 promotes cancer progression by promoting apoptosis, inhibiting cell cycle and EMT, activating hormone AR activity, activating PI3K/AKT pathway, RASMAPK pathway, and RTK pathway. Finally, we also found that the DDR1 gene was positively associated with stemness scores in most tumors.
Conclusion:
Our findings demonstrate that DDR1 exhibits diagnostic utility and holds promising translational potential as a therapeutic target across multiple cancer types.
Insights
Discoid Domain Receptor 1 (DDR1) shows diagnostic utility and therapeutic potential in multiple cancers. Targeting DDR1 may offer new treatment strategies for various cancer types, impacting patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Cancer poses a significant global health challenge with limited therapeutic options.
- Discoid Domain Receptors (DDRs), particularly DDR1, are emerging targets but their pan-cancer roles are unclear.
Purpose of the Study:
- To investigate the regulatory mechanisms and diagnostic potential of DDR1 in various cancer types.
- To elucidate DDR1's association with clinical prognosis and immune microenvironment.
Main Methods:
- Utilized online databases including UCSC, SangerBox, GEPIA, GSCA, and GeneMANIA.
- Analyzed DDR1 expression, clinical correlation, immune interactions, and pathway activation across multiple cancers.
Main Results:
- DDR1 expression varied significantly with tumor stage and correlated with prognosis in five cancers.
- DDR1 inversely correlated with immune checkpoints and cell infiltration in some cancers.
- DDR1 promotes cancer progression via apoptosis, cell cycle, EMT, and key signaling pathways, and is linked to stemness.
Conclusions:
- DDR1 demonstrates diagnostic value and therapeutic promise across multiple cancer types.
- DDR1 represents a potential translational target for novel cancer therapies.
More Related Videos
Related Concept Videos
01:16Therapeutic Drug Monitoring: Overview and Classification
01:29Therapeutic Drug Monitoring: Affecting Factors
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase